Physician profile
Timothy Lamb
NPI 1942279260
$9,273.95
in general payments reported to CMS, 2019-2025
36 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $1,230 · 2021: $1,489 · 2022: $1,529 · 2023: $2,073 · 2024: $980 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,610.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,306.20 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,281.17 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $862.21 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $669.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $459.08 | 2019-2021 | |
| Amgen INC. | $421.38 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.30 | 2019-2024 | Jardiance, Tradjenta, Stiolto Respimat |
| Abbvie INC. | $357.50 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $268.31 | 2019-2023 | |
| Astellas Pharma US INC | $234.51 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $205.13 | 2023-2025 | Cologuard Collection Kit |
| Nevro Corp. | $191.37 | 2021-2023 | Senza |
| Amarin Pharma, INC. | $177.65 | 2019-2022 | |
| Eisai INC. | $101.46 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $84.83 | 2020-2023 | Livalo, Seglentis |
| Amneal Pharmaceuticals LLC | $68.45 | 2023-2024 | Unithroid |
| Arbor Pharmaceuticals, INC. | $67.10 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $61.40 | 2022-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $61.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $60.12 | 2021 | |
| Abbott Laboratories | $47.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.80 | 2023 | Xifaxan |
| Esperion Therapeutics, INC. | $31.00 | 2020-2021 | |
| Pulmonx Corporation | $27.80 | 2022 | |
| Cequr Corporation | $24.28 | 2025 | Cequr Simplicity |
| Teva Pharmaceuticals USA, INC. | $23.64 | 2021 | |
| Genentech USA, INC. | $20.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.34 | 2020 | |
| Acadia Pharmaceuticals INC | $14.07 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.06 | 2022 | |
| Lucid Diagnostics INC. | $13.11 | 2024 | |
| Allergan, INC. | $13.02 | 2020 | |
| Vistapharm, INC. | $12.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.